These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38324026)

  • 1. Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGFβ Signaling.
    Tao ZY; Wang L; Zhu WY; Zhang G; Su YX
    Cancer Res Commun; 2024 Feb; 4(2):418-430. PubMed ID: 38324026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.
    Ludwig N; Wieteska Ł; Hinck CS; Yerneni SS; Azambuja JH; Bauer RJ; Reichert TE; Hinck AP; Whiteside TL
    Mol Cancer Ther; 2021 Jun; 20(6):1102-1111. PubMed ID: 33850003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
    Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
    Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
    Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
    Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
    Jiang C; Yuan F; Wang J; Wu L
    Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
    Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
    J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.
    Chiang IT; Lee YH; Tan ZL; Hsu FT; Tu HF
    Biomed Pharmacother; 2022 Mar; 147():112661. PubMed ID: 35092865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
    Kenison JE; Wang Z; Yang K; Snyder M; Quintana FJ; Sherr DH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
    Sasabe E; Tomomura A; Yamamoto T
    J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
    Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
    Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
    Wang X; Zhao W; Zhang W; Wu S; Yan Z
    J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
    Cui B; Chen J; Luo M; Liu Y; Chen H; Lü D; Wang L; Kang Y; Feng Y; Huang L; Zhang P
    Int J Oral Sci; 2021 Mar; 13(1):8. PubMed ID: 33692335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.